Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

This study has been completed.
Sponsor:
Collaborator:
Sarcoma Alliance for Research through Collaboration (SARC)
Information provided by (Responsible Party):
Threshold Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT01440088
First received: September 20, 2011
Last updated: June 1, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2016
  Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):